US 12,747,286 B2 · Means for specifically eliminating perilipin-1 fragment presenting adipocytes

Abstract

The present invention relates to an antigen-binding peptide specifically binding to at least one perilipin-1 epitope as defined herein. The present invention further relates to an antigen-binding peptide for use in the prevention or treatment of obesity. Furthermore, the present invention relates to a bispecific antigen-binding peptide comprising a first binding site specifically binding to a perilipin-1 epitope and a second binding site, and use thereof. The present invention also relates to a pharmaceutical composition, comprising an antigen-binding peptide or a bispecific antigen-binding peptide, for use in the prevention or treatment of obesity. The present invention further relates to an isolated nucleic acid encoding for an antigen-binding peptide or a bispecific antigen-binding peptide. Furthermore, the present invention relates to a recombinant cell comprising said nucleic acid and to a method of producing a means for specifically targeting perilipin-1 fragment presenting adipocytes.

An antigen-binding peptide specifically binding to at least one perilipin-1 epitope selected from the group consisting of amino acid sequences LTLLDGDLPE (SEQ ID NO:

1), EKIASELK (SEQ ID NO:
2), PSLLSRVGALTN (SEQ ID NO:
5), and PWLHSLAA (SEQ ID NO:
6);
wherein said antigen-binding peptide comprises
(i) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:18, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:19, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:20, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:21, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:22, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:23;
or
(ii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:24, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:25, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:26, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:27, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:28, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:29;
or
(iii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:30, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:31, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:32, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:33, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:34, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:35;
or
(iv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:36, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:37, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:38, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:39, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:40, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:41;
or
(v) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:42, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:43, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:44, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:45, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:46, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:47;
or
(vi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:48, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:49, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:50, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:51, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:52, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:53;
or
(vii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:54, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:55, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:56, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:57, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:58, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:59;
or
(viii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:60, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:61, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:62, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:63, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:64, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:65;
or
(ix) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:66, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:67, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:68, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:69, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:70, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:71;
or
(x) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:72, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:73, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:74, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:75, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:76, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:77;
or
(xi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:78, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:79, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:80, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:81, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:82, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:83;
or
(xii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:84, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:85, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:86, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:87, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:88, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:89;
or
(xiii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:90, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:91, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:92, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:93, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:94, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:95;
or
(xiv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:96, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:97, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:98, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:99, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:100, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:101;
or
(xv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:102, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:103, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:104, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:105, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:106, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:107;
or
(xvi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:108, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:109, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:110, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:111, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:112, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:113;
or
(xvii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:114, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:115, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:116, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:117, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:118, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:119;
or
(xviii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:120, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:121, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:122, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:123, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:124, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:125;
or
(xix) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:126, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:127, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:128, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:129, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:130, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:131;
or
(xx) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:132, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:133, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:134, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:135, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:136, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:137;
or
(xxi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:138, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:139, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:140, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:141, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:142, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:143;
or
(xxii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:144, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:145, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:146, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:147, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
148, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:149;
or
(xxiii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:150, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:151, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:152, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:153, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:154, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:155;
or
(xxiv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:156, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:157, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:158, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:159, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:160, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:161;
or
(xxv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:162, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
163, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:164, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:165, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
166, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:167;
or
(xxvi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:168, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:169, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:170, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:171, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:172, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:173;
or
(xxvii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:174, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:175, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:176, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:177, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:178, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:179;
or
(xxviii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
180, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
181, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
182, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
183, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
184, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
185;
or
(xxix) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:186, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:187, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:188, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:189, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
190, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:191;
or
(xxx) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:192, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:193, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:194, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:195, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:196, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:197;
or
(xxxi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:198, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:199, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:200, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:201, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:202, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:203;
or
(xxxii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:204, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:205, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:206, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:207, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:208, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:209;
or
(xxxiii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
210, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
211, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
212, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
213, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
214, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
215;
or
(xxxiv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
216, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
217, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
218, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
219, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
220, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
221;
or
(xxxv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:222, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:223, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:224, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:225, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:226, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:227;
or
(xxxvi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
228, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
229, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
230, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
231, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
232, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
233;
or
(xxxvii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
234, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
235, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
236, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
237, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
238, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
239;
or
(xxxviii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
240, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
241, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
242, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
243, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
244, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
245;
or
(xxxix) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
246, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
247, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
248, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:
249, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:
250, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:
251;
or
(xl) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:252, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:253, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:254, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:255, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:256, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:257;
or
(xli) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:258, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:259, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:260, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:261, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:262, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:263;
or
(xlii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:264, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:265, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:266, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:267, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:268, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:269;
or
(xliii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:270, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:271, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:272, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:273, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:274, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:275;
or
(xliv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:276, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:277, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:278, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:279, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:280, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:281;
or
(xlv) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:282, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:283, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:284, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:285, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:286, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:287;
or
(xlvi) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:288, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:289, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:290, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:291, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:292, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:293;
or
(xlvii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:294, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:295, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:296, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:297, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:298, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:299;
or
(xlviii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:300, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:301, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:302, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:303, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:304, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:305;
or
(xlix) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:306, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:307, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:308, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:309, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:310, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:311;
or
(l) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:312, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:313, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:314, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:315, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:316, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:317;
or
(li) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:318, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:319, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:320, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:321, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:322, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:323;
or
(lii) a heavy chain CDR1 region comprising the amino acid sequence of SEQ ID NO:324, a heavy chain CDR2 region comprising the amino acid sequence of SEQ ID NO:325, a heavy chain CDR3 region comprising the amino acid sequence of SEQ ID NO:326, a light chain CDR1 region comprising the amino acid sequence of SEQ ID NO:327, a light chain CDR2 region comprising the amino acid sequence of SEQ ID NO:328, and a light chain CDR3 region comprising the amino acid sequence of SEQ ID NO:329.

151 more elements

Means for specifically eliminating perilipin-1 fragment presenting adipocytes

Life of this patent

Means for specifically eliminating perilipin-1 fragment presenting adipocytes

Life of this patent

Abstract

Claims17